Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer.

Kathryn C ArbourHira RizviAndrew J Plodkowski Matthew D Hellmann Andrea KnezevicGlenn HellerHelena A YuMarc LadanyiMark G KrisMaria E ArcilaCharles M RudinPiro LitoGregory J Riely

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

We provide outcome data for a large series of patients with KRAS G12C-mutant NSCLC with available therapies, demonstrating that responses and duration of benefit with available therapies are similar to those seen in patients with KRAS non-G12C mutations. Strategies to incorporate new targeted therapies into the current treatment paradigm will need to consider outcomes specific to patients harboring KRAS G12C mutations.

Keyphrases

wild type
end stage renal disease
newly diagnosed
small cell lung cancer
ejection fraction
chronic kidney disease
type diabetes
big data
data analysis
tyrosine kinase
patient reported